Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Travoprost vs timolol in pediatric glaucoma
NL-OMON38960Phase 3Withdrawn
- Sponsor
- Alcon Inc.
- Start
- Feb 2013
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, double-blind trial of travoprost and timolol in Childhood Glaucoma and ocular hypertension, sponsored by Alcon Inc. Primary endpoint: Change from baseline in intraocular pressure at Month 3. Planned start Feb 2013; status: withdrawn.
02
Drugs
travoprosttimolol
03
Conditions
Childhood Glaucomaocular hypertension
Beyond the preview
Go deeper on NL-OMON38960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38960.